Bhuyan Muhammad Ar, Al Mahtab Mamun, Ashab Eshita, Haque Md Jahirul, Hoque Syed Md M, Faizul Huq Akm, Islam Md Atikul, Choudhury Nuzhat, Alia Reema A, Mahtab Musarrat, Khan Md Sakirul I, Akbar Sheikh Mf
Department of Medicine, Shaheed Syed Nazrul Islam Medical College Hospital, Kishoreganj, Bangladesh.
Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
Euroasian J Hepatogastroenterol. 2020 Jan-Jun;10(1):27-30. doi: 10.5005/jp-journals-10018-1317.
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has induced a sense of panic around the world as the disease is highly contagious and has been spreading in full swing during last 5 months causing millions of COVID-19 patients and hundreds of thousands of deaths. Bangladesh, a country of 170 million people, is not an exception regarding COVID-19; it has reported several thousand COVID-19 patients with several hundred of deaths. This observational study has been planned to assess the scope and limitation of management strategy against COVID-19 patients in a medical college hospital of Bangladesh with available drugs in a real-life situation.
All patients in this cohort (: 33) were positive for SARS-CoV-2 by polymerase chain reaction (PCR) and they attended the hospital with variable presenting symptoms those ranged from cough and fever to respiratory distress and pneumonia. As per the protocol, the patients were regularly evaluated for several parameters of COVID-19-related pathology. Before discharge, they were checked for SARS-CoV-2 for 2 consecutive times. The management strategy included standard of care (SoC) and administration of hydroxychloroquine and azythromycin, available in Bangladesh.
Out of total 33 patients, 1 patient died at day 4 day after admission. Two patients developed severe complications and were referred to tertiary hospital in Dhaka (2 and 3 days after admission), the capital of Bangladesh, where they recovered and were discharged from hospital after being SARS-CoV-2 negative. The rest 30 patients were discharged from the medical college hospital after being negative for SARS-CoV-2 in two subsequent assessments and improvement of their COVID-related symptoms. The average hospital stay of these patients was 14.5 days with a range of 10-24 days.
It seems that most of the COVID-19 patients may be adequately managed by standard of care management with drug support. However, early diagnosis and hospitalization with adequate care may be important variables for better survival. These factors may be properly ensured if the patient burden remains at a palatable level in forthcoming days in Bangladesh.
Bhuyan MAR, Al Mahtab M, Ashab E, Treatment of COVID-19 Patients at a Medical College Hospital in Bangladesh. Euroasian J Hepato-Gastroenterol 2020;10(1):27-30.
2019冠状病毒病(COVID-19)由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起,由于该疾病具有高度传染性且在过去5个月中迅速蔓延,已导致数百万COVID-19患者和数十万人死亡,在全球引发了恐慌。孟加拉国是一个拥有1.7亿人口的国家,在COVID-19方面也不例外;该国已报告了数千例COVID-19患者和数百例死亡病例。本观察性研究旨在评估孟加拉国一所医学院附属医院在实际情况下使用现有药物对COVID-19患者的管理策略的范围和局限性。
该队列中的所有患者(n = 33)通过聚合酶链反应(PCR)检测SARS-CoV-2呈阳性,他们因从咳嗽、发热到呼吸窘迫和肺炎等各种不同的症状前来就诊。按照方案,对患者进行了COVID-19相关病理的多个参数的定期评估。出院前,连续两次对他们进行SARS-CoV-2检测。管理策略包括孟加拉国现有的标准治疗(SoC)以及羟氯喹和阿奇霉素的使用。
在总共33例患者中,1例患者在入院后第4天死亡。2例患者出现严重并发症,并被转诊至孟加拉国首都达卡的一家三级医院(入院后2天和3天),他们在那里康复,并在SARS-CoV-2检测呈阴性后出院。其余30例患者在随后两次评估SARS-CoV-2呈阴性且COVID相关症状改善后从医学院附属医院出院。这些患者的平均住院时间为14.5天,范围为10 - 24天。
似乎大多数COVID-19患者可以通过标准治疗管理并辅以药物支持得到充分治疗。然而,早期诊断和充分护理下的住院治疗可能是提高生存率的重要变量。如果未来几天孟加拉国的患者负担保持在可承受水平,这些因素可能会得到妥善保障。
Bhuyan MAR, Al Mahtab M, Ashab E, 孟加拉国一所医学院附属医院对COVID-19患者的治疗。《欧亚肝脏胃肠病学杂志》2020;10(1):27 - 30。